Analysis of Therapeutic Efficacy and Adverse Prognostic Factors of Secondary Central Nervous System Lymphoma
10.19746/j.cnki.issn1009-2137.2024.05.018
- VernacularTitle:继发中枢神经系统淋巴瘤的治疗效果及预后不良因素分析
- Author:
Ning WANG
1
;
Fei-Li CHEN
;
Yi-Lan HUANG
;
Xin-Miao JIANG
;
Xiao-Juan WEI
;
Si-Chu LIU
;
Yan TENG
;
Lu PAN
;
Ling HUANG
;
Han-Guo GUO
;
Zhan-Li LIANG
;
Wen-Yu LI
Author Information
1. 华南理工大学医学院,广东广州 510006
- Keywords:
secondary central nervous system lymphoma;
gene mutation;
prognostic factor;
risk factor
- From:
Journal of Experimental Hematology
2024;32(5):1420-1426
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the therapeutic efficacy and prognostic factors of induction therapy for secondary central nervous system lymphoma(SCNSL).Methods:Clinical data of patients diagnosed with SCNSL from 2010 to 2021 at Guangdong Provincial People's Hospital were retrospectively collected.A retrospective cohort study was performed on all and grouped patients to analyze the efficacy and survival.Multivariate logistic regression analysis was used to explore the adverse prognostic factors.Results:Thirty-seven diffuse large B-cell lymphoma patients with secondary central involvement were included in the research.Their 2-year overall survival(OS)rate was 46.01％and median survival time was 18.1 months.The 2-year OS rates of HD-MTX group and TMZ group were 34.3％and 61％,median survival time were 8.7 and 38.3 months,and median progression-free survival time were 8.1 and 47 months,respectively.Multivariate logistic regression analysis showed that age,sex,IPI,Ann Arbor stage were correlated with patient survival time.The median survival time of patients with CD79B,KMT2D,CXCR4.ERBB2,TBL1XR1,BTG2,MYC,MYD88,and PIM1 mutations was 8.2 months,which was lower than the overall level.Conclusion:HD-MTX combined with TMZ as the first-line strategy may improve patient prognosis,and early application of gene sequencing is beneficial for evaluating prognosis.
